These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3623063)

  • 1. [Status of the immune system in multiple myeloma during polychemotherapy].
    Golenkov AK; Cheredeev AN; Zlatkina AR; Konstantinpva NA; Mattes KH
    Gematol Transfuziol; 1987 Jun; 32(6):9-13. PubMed ID: 3623063
    [No Abstract]   [Full Text] [Related]  

  • 2. [The characteristics of the immunological indices in multiple myeloma during polychemotherapy].
    Abdulkadyrov KM; Bessmel'tsev SS
    Lik Sprava; 1995; (3-4):75-80. PubMed ID: 8819928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunological and rheological disorders in multiple myeloma patients].
    Abdulkadyrov KM; Bessmel'tsev SS; Liubimova NIu
    Ter Arkh; 1991; 63(7):122-6. PubMed ID: 1788790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Importance of immunological and cytochemical studies of the peripheral blood lymphocytes in myeloma patients during polychemotherapy].
    Golenkov AK; Andreeva OK; Zlatkina AR; Cheredeev AN
    Gematol Transfuziol; 1984 Feb; 29(2):19-22. PubMed ID: 6608470
    [No Abstract]   [Full Text] [Related]  

  • 5. Cellular in vitro immune function in multiple myeloma patients after high-dose chemotherapy and autologous peripheral stem cell transplantation.
    Lindemann M; Schuett P; Moritz T; Ottinger HD; Opalka B; Seeber S; Nowrousian MR; Grosse-Wilde H
    Leukemia; 2005 Mar; 19(3):490-2. PubMed ID: 15674357
    [No Abstract]   [Full Text] [Related]  

  • 6. [Individualization of polychemotherapy for stage III breast cancer based on immunologic status].
    Sabala PI
    Vopr Onkol; 1984; 30(11):44-8. PubMed ID: 6516259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic lysozyme administration as a tool for immunopotentiation in patients with multiple myeloma.
    Vacca A; Campobasso N; Iodice G; Ronco M; Dammacco F
    Chemioterapia; 1985 Apr; 4(2):147-55. PubMed ID: 3924421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Polychemotherapy versus melphalan-prednisone in multiple myeloma].
    Leoni P; Salvi A; Brianzoni MF; Centurioni R; Montillo M; Olivieri A
    G Clin Med; 1986 Dec; 67(5-6):291-6. PubMed ID: 3609590
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comparative evaluation of the effectiveness of mono- and polychemotherapy programs in patients with multiple myeloma].
    Abdulkadyrov KM; Bessmel'tsev SS
    Klin Med (Mosk); 1992; 70(9-10):57-60. PubMed ID: 1474818
    [No Abstract]   [Full Text] [Related]  

  • 10. [Monochemotherapy and polychemotherapy of multiple myeloma].
    Kraj M; Maj S; Rostkowska J; Pogłód R; Słomkowski M
    Nowotwory; 1984; 34(1):65-75. PubMed ID: 6377239
    [No Abstract]   [Full Text] [Related]  

  • 11. [Polychemotherapy of multiple myeloma using pafencil (COPPaf protocol)].
    Tsykalov VA; Zhuravlev VS; Mokeeva RA
    Gematol Transfuziol; 1989 Apr; 34(4):56-8. PubMed ID: 2744382
    [No Abstract]   [Full Text] [Related]  

  • 12. [Assessment of the immunological status of chondrosarcoma patients].
    Korolev VI; Kamenets LIa
    Eksp Onkol; 1986; 8(1):63-5. PubMed ID: 3948760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of chemotherapy on the killer activity of the peripheral blood leukocytes in patients with multiple myeloma].
    Vozniuk VP
    Lik Sprava; 1998; (2):88-91. PubMed ID: 9670667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemotherapy of multiple myeloma].
    Golenkov AK
    Gematol Transfuziol; 1989 Apr; 34(4):11-5. PubMed ID: 2744373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of systemic chemotherapy on clinical status and biological and immunologic markers in patients with breast cancer].
    Orlova RV; Chernetsova LF; Matveeva ON
    Vopr Onkol; 2007; 53(4):414-8. PubMed ID: 17969403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma.
    Ray A; Das DS; Song Y; Hideshima T; Tai YT; Chauhan D; Anderson KC
    Leukemia; 2018 Mar; 32(3):843-846. PubMed ID: 29104288
    [No Abstract]   [Full Text] [Related]  

  • 17. [The polychemotherapy of patients with multiple myeloma].
    Abdulkadyrov KM; Bessmel'tsev SS
    Vopr Onkol; 1992; 38(3):345-51. PubMed ID: 1300725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistant multiple myeloma treated with mitozantrone in combination with vincristine and dexamethasone (MOD).
    Phillips JK
    Eur J Haematol; 1989 Jan; 42(1):109-10. PubMed ID: 2914592
    [No Abstract]   [Full Text] [Related]  

  • 19. A case of IgE myeloma: methodology and review of the literature.
    Allevato PA; Deegan MJ; Chu JW; Perry MB; Barth CL
    Henry Ford Hosp Med J; 1984; 32(2):134-41. PubMed ID: 6439692
    [No Abstract]   [Full Text] [Related]  

  • 20. [IgM myeloma].
    Assaf ME; Pizzolato MA; De María HE; Gasparini S; Burucua JE
    Sangre (Barc); 1983; 28(5):642-7. PubMed ID: 6420914
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.